In contrast to anti-Yo negative controls, 65% of anti-Yo PCD tumors presented one or more somatic mutations in genes encoding the Yo antigen, with a predominance of missense mutations, and 59% of anti-Yo PCD tumors showed recurrent gains of the CDR2L gene with tumor protein overexpression. The gene discussed is CDR2; the disease is neoplasm.